For any subsequent calendar quarters that the Part B rebatable biosimilar biological product appears as currently in shortage, CMS would reduce the rebate amount in accordance with the drug shortages reduction proposed in 427.401, starting with the highest reduction (that is, 75 percent for a plasma-derived product and 25 percent for a Part B rebatable drug that is not a plasma-derived product)
It also lowers the pH level, lowering the chances of metabolite detection
Mouth swab tests are much easier to pass than a urine or blood test, since they usually can't detect drug use for more than a couple of days
We seek comment on whether we should consider finalizing a specified duration that HCPCS code GFCI1 could be billed) following discharge, for example, allowing this code to be billed for up to two months following discharge or whether a longer duration would be appropriate, the number of calls per month, the billing structure (for example, four calls for each discharged patient), and any other relevant feedback
